News in brief: Diet and lifestyle inertia even with type 2 diabetes; New drug for adult growth hormone deficiency; Diabetes patients skip pre-clinic checks

Tuesday, 15 Mar 2022

Diet and lifestyle inertia even with type 2 diabetes

A diagnosis of type 2 diabetes does not appear to be the wake-up call people need to adopt healthier lifestyles.

Data from the NSW Adult Population Health Survey between 2004-2007 and 2016-2019 found an increasing trend in T2D prevalence over time.

Despite this, overweight and obesity in people with type 2 diabetes was relatively stable over time, there was a decline in the reporting of adequate fruit or vegetable consumption, and a decline in the reporting of adequate levels of physical activity.

Rates of following a special diet reduced from 73.6% to 55.9% over the study period.

The study authors said the trends in lifestyle risk factors in NSW adults with type 2 diabetes demonstrate a lack of progress in achieving diabetes self-management recommendations.

“They mirror trends in the NSW adult population without diabetes and are accentuated by a declining adoption of lifestyle diabetes management strategies, including trying to lose weight, following a special diet, and exercising most days.”

Read more in Preventive Medicine

New drug approved for adult growth hormone deficiency

Somapacitan (Sogroya) has been TGA-approved for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (AGHD).

The long‑acting recombinant human growth hormone derivative works either directly via the growth hormone (GH)‑receptor and/or indirectly via insulin like growth factor‑1 (IGF-I) to normalise body composition and metabolic action.

“Somapacitan should be initiated and monitored by physicians who are appropriately qualified and experienced in the diagnosis and management of adult patients with growth hormone deficiency (for example, endocrinologists),” the ARTG said.

Somapacitan has been approved under the Black Triangle Scheme to encourage the reporting of adverse events associated with its use as a new prescription medicine.

Diabetes patients skip pre-clinic checks

Adults with type 1 diabetes using glucose sensors and/or insulin pumps who do not review their device data before attending a diabetes clinic are not squeezing optimum benefit from their technology.

A prospectively survey of 138 adults attending an Australian public hospital found 79% uploaded and 32% reviewed their device data pre-clinic. Individuals using pumps with sensors were most likely to review their data.

Median HbA1c levels were lower in those who did review their data compared to those who did not (50.8 mmol/mol vs. 61.8 mmol/mol, p=0.0001).

The survey noted that most patients (89%) were interested in education.

“Although diabetes technology has improved glycaemia in T1DM, the benefits may be maximised through device-specific education programs enhancing self-management,” it said.

Read more in Diabetes Technology & Therapeutics

Already a member?

Login to keep reading.

Email me a login link

© 2022 the limbic